Communiqués Intellia Therapeutics, Inc.

Actions

NTLA

US45826J1051

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/06/2026			Après clôture 02:00:00
12,20 ^USD	-5,35%		11,62	-4,75%

13/05	Transcript : Intellia Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:40 PM
11/05	Intellia Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

05/06	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
01/06	Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026	AQ
11/05	Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates	AQ
05/05	Intellia Therapeutics to Participate in Upcoming Investor Conferences	AQ
04/05	Intellia Initiates Rolling BLA Submission For In Vivo CRISPR Therapy In Hereditary Angioedema	AQ
01/05	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
29/04	Intellia Therapeutics Announces Pricing of Public Offering of Common Stock	AQ
27/04	Intellia Announces Proposed Public Offering of Common Stock	AQ
27/04	Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026	AQ
27/04	Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing	AQ
27/04	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema	AQ
24/04	Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026	AQ
03/04	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
06/03	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04/03	Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran, Hereditary Angioedema Patient-Focused Research at AAAAI 2026	AQ
03/03	Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026	AQ
02/03	Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM	AQ
26/02	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates	AQ
24/02	Intellia Therapeutics to Participate in Upcoming Investor Conferences	AQ
20/02	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates	AQ
19/02	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates	AQ
06/02	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
28/01	Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine	AQ
27/01	Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN	AQ
07/01	Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ